MARKETS 1h ago
Mankind Pharma Q2 profit rises 38% to Rs 716 crore
Economic Times Stocks
Published 27 Oct 2026, 02:00 am IST
ReutersThe company had posted a profit after tax (PAT) of ₹520.2 crore in the year-ago period, according to a regulatory filing. Revenue from operations increased to ₹4,337.9 crore during the quarter under review as against ₹3,697.2 crore in the year-ago period, the company said in a regulatory filing.
"Our disciplined execution and strengthening business fundamentals resulted in strong performance. Our recent acquisition of Armed Cell Therapeutics marks strategic entry into Next-Generation CAR-T therapies, strengthening R&D capabilities for future growth," vice chairman & managing director Rajeev Juneja said.
Originally reported by Economic Times Stocks.Source: economictimes.indiatimes.com
Related reads
Livemint Markets · 16m
Q2 results 2026 today, schedule: L&T, Maruti Suzuki - 100 more firms to declare quarterly earnings; Oct 27 Tue list
Livemint Companies · 20m
Mint explainer: what’s next for Tata Motors as it prepares to integrate Iveco?
Economic Times Markets · 32m
JSW Steel among 5 stocks showing the White Marubozu pattern
Economic Times Stocks · 37m
Ather Energy among 5 stocks showing RSI trending up